| Literature DB >> 19068113 |
Mehdi Merouani1, Bruno Guignard, François Vincent, Stephen W Borron, Philippe Karoubi, Jean-Philippe Fosse, Yves Cohen, Christophe Clec'h, Eric Vicaut, Carole Marbeuf-Gueye, Frederic Lapostolle, Frederic Adnet.
Abstract
INTRODUCTION: The rate of weaning of vasopressors drugs is usually an empirical choice made by the treating in critically ill patients. We applied fuzzy logic principles to modify intravenous norepinephrine (noradrenaline) infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19068113 PMCID: PMC2646320 DOI: 10.1186/cc7149
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Scheme for a fuzzy logic based norepinephrine controller. The monitor was connected to a computer that converted the mean arterial pressure (MAP) and norepinephrine infusion rate into fuzzy datasets and automatically calculated the required change in rate of infusion. MAP level and MAP variation (ΔMAP) – the variables to be controlled – are the outputs of the controlled system, whereas the norepinephrine infusion rate is the input to be adjusted to reach the desired MAP value. The infusion rate changed automatically every 7 minutes after analysis of the MAP and the ΔMAP.
Baseline characteristics of the patients
| Variable | Control group (n = 20) | Fuzzy group (n = 19) |
| Age (years) | 66 ± 12 | 64 ± 12 |
| Male sex | 70% | 58% |
| Weight (kg) | 67 ± 15 | 71 ± 14 |
| Prior or coexisting conditions | ||
| Chronic obstructive pulmonary disease | 40% | 37% |
| Congestive cardiomyopathy | 0% | 5% |
| Diabetes | 10% | 5% |
| Liver disease | 2% | 0% |
| Chronic renal failure | 0% | 0% |
| Cancer | 30% | 26% |
| Activity limitation (A/B/C/D)a | 3/8/7/2 | 4/10/5/0 |
| McCabe classification (1/2/3)b | 10/6/4 | 12/4/3 |
| Recent surgical history | 20% | 16% |
| Disease severity | ||
| Temperature (°C) | 36.8 ± 1.8 | 37.7 ± 1.5 |
| Heart rate (beats/minute) | 119 ± 26 | 103 ± 27 |
| Systolic blood pressure (mmHg) | 84 ± 14 | 80 ± 22 |
| Mean blood pressure (mmHg) | 61 ± 12 | 59 ± 16 |
| White cell count (/mm3) | 16,100 ± 8,800 | 17,600 ± 12,000 |
| Platelet (× 103/μl) | 263 ± 198 | 262 ± 138 |
| Haematocrit (%) | 30 ± 7 | 32 ± 6 |
| Blood urea nitrogen (mmol/l) | 10.3 ± 6.3 | 10.4 ± 6.2 |
| Creatinine (μmol/l) | 113 ± 70 | 136 ± 88 |
| Total bilirubin (μmol/l) | 12.3 | 15.5 |
| Lactate (mmol/l) | 2.5 ± 2.1 | 2.0 ± 0.8 |
| Pa | 166 ± 81 | 181 ± 93 |
| Arterial pH | 7.28 ± 0.14 | 7.31 ± 0.09 |
| SAPS II scale | 62 ± 23 | 58 ± 16 |
| Initial SOFA score | 11.0 ± 2.5 | 11.2 ± 3.3 |
| Norepinephrine infusion at the time of randomization (μg/kg per minute) | 0.6 ± 0.4 | 0.8 ± 0.4 |
| Site of infectionc | ||
| Lung | 75% | 63% |
| Abdomen | 25% | 10% |
| Urinary tract | 5% | 15% |
| Other | 5% | 10% |
| Bacterial pathogen staining | ||
| Gram-negative | 40% | 58% |
| Gram-positive | 25% | 10% |
| Unconfirmed | 35% | 32% |
Values are expressed as number, percentage or mean ± standard deviation. Percentages may not total 100 because of rounding. aLevels of activity were defined as follows (Knaus Chronic Health Status score): A = prior good health, no functional limitations; B = mild to moderate limitation of activity because of a chronic medical problem; C = chronic disease producing serious but not incapacitating limitation of activity; and D = severe restriction of activity due to disease, includes persons bedridden or institutionalized due to illness. bMcCabe classification: 1 = nonfatal disease; 2 = ultimately fatal disease; and 3 = rapidly fatal disease. cThe site of infection was either documented or presumed on the basis of clinical findings. PaO2/FiO2, arterial oxygen tension/fractional inspuired oxygen ratio; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.
Figure 2Kaplan-Meier curves demonstrating the probability of being on norepinephrine therapy during the study. Comparisons between the time distribution of both groups were performed by means of the generalized Wicolxon (Breslow) test. Competitive risk analysis was performed when the occurrence of death interacted with the event under study (two patients); P < 0.0001.
Outcome measures
| Measure | Control group (n = 20) | Fuzzy group (n = 19) | |
| Shock duration (hours) | 57.5 (43.7–117.5) | 28.5 (20.5–42) | <0.0001 |
| Weaning failure (%) | 2 (10) | 0 (0) | 0.49 |
| Mortality at 28 days (%) | 7 (37) | 7 (35) | 0.80 |
| Mechanical ventilation (days) | 20 (11–32) | 15 (7–38) | 0.96 |
| ICU-free days at day 28 | 7 (0–18) | 3 (0–17) | 0.74 |
| Total norepinephrine infuseda (μg/kg) | 1.4 (0.6–2.7) | 0.6 (0.2–1.0) | <0.01 |
| Crystalloid/colloida (ml) | 8750 (6000–14000) | 6000 (3275–7512) | 0.47 |
Values are expressed as median (interquartile range). aTotal amount administered during shock. ICU, intensive care unit.
Figure 3Time dependence in norepinephrine infusion rate and mean arterial pressure. (a) Norepinephrine (NE) infusion rate and mean arterial pressure (MAP) over time for a representative patient included in the control group. There is a linear decrease in norepinephrine infusion rate. (b) Norepinephrine infusion rate and MAP over time for a representative patient included in the fuzzy group. The change in norepinephrine infusion rate is more or less sinusoidal.